Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
30.56
+1.39 (4.78%)
At close: Apr 28, 2026, 4:00 PM EDT
30.60
+0.04 (0.13%)
After-hours: Apr 28, 2026, 7:18 PM EDT
Beam Therapeutics Employees
Beam Therapeutics had 511 employees as of December 31, 2025. The number of employees increased by 28 or 5.80% compared to the previous year.
Employees
511
Change (1Y)
28
Growth (1Y)
5.80%
Revenue / Employee
$273,470
Profits / Employee
-$156,540
Market Cap
3.06B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 249 |
| Celldex Therapeutics | 198 |
| Soleno Therapeutics | 182 |
| Immunome | 177 |
| Disc Medicine | 155 |
| IDEAYA Biosciences | 145 |
BEAM News
- 27 days ago - Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine - GlobeNewsWire
- 4 weeks ago - Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels - Benzinga
- 4 weeks ago - Beam Therapeutics Transcript: Study result - Transcripts
- 4 weeks ago - Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development - GlobeNewsWire
- 2 months ago - What's Going On With Beam Therapeutics Stock? - Benzinga
- 2 months ago - Beam Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - GlobeNewsWire
- 2 months ago - Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street - GlobeNewsWire